DCOY logo

DECOY THERAPEUTICS INC

DCOYNASDAQ
πŸ† #5155 by market capEarnings Nov 12US Equity
$0.99β–Ό $0.09 (βˆ’8.33%)
Market closed Β· at close
πŸ””
Track DCOY
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 8.3%
7dβ–Ό 8.3%
14dβ–Ό 18.9%
30dβ–Ό 53.1%
ytdβ–Ό 87.1%
1yβ–Ό 97.8%
🏦Market Cap
$2M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
48.6%
Healthy
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
11.4x
Elevated
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.99 – $0.99
52-Week Range
$0.90 – $47.64
Volume (shares)
820
Avg Volume (shares)
β€”
Shares Outstanding
2.4M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
11.4x
EPS (TTM)
$-934.89
Dividend Yield
β€”
Dilution (1yr)
+401.3%
DCOY logo

DECOY THERAPEUTICS INC

DCOY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$13Mβ–² +120.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5Mβ–² +6.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
482Kβ–² +401.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$11Mβ–² +$8M YoY
StockOtter Β· stockotter.space

About DECOY THERAPEUTICS INC

Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.